Login / Signup

Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells.

Patrick D RädlerBarbara L WehdeAleata A TriplettHridaya ShresthaJonathan H ShepherdAdam D PfefferleHallgeir RuiRobert D CardiffCharles M PerouKay-Uwe Wagner
Published in: Nature communications (2021)
Claudin-low breast cancer represents an aggressive molecular subtype that is comprised of mostly triple-negative mammary tumor cells that possess stem cell-like and mesenchymal features. Little is known about the cellular origin and oncogenic drivers that promote claudin-low breast cancer. In this study, we show that persistent oncogenic RAS signaling causes highly metastatic triple-negative mammary tumors in mice. More importantly, the activation of endogenous mutant KRAS and expression of exogenous KRAS specifically in luminal epithelial cells in a continuous and differentiation stage-independent manner induces preneoplastic lesions that evolve into basal-like and claudin-low mammary cancers. Further investigations demonstrate that the continuous signaling of oncogenic RAS, as well as regulators of EMT, play a crucial role in the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics of claudin-low mammary cancer cells.
Keyphrases
  • stem cells
  • wild type
  • transcription factor
  • squamous cell carcinoma
  • bone marrow
  • type diabetes
  • metabolic syndrome
  • epithelial mesenchymal transition
  • adipose tissue